Fullerene-based low toxic nanocationite particles (porphyrin adducts of cyclohexyl fullerene-C(60)) to treat hypoxia-induced mitochondrial dysfunction in mammalian heart muscle.

[1]  R. Mahato.  Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids , 2009 .

[2]  A. Domb,et al.  Nanoparticles for Crossing Biological Membranes , 2007 .

[3]  A. Buchachenko,et al.  Magnetic isotope effect of magnesium in phosphoglycerate kinase phosphorylation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  G. Andrievsky,et al.  Is the C60 Fullerene Molecule Toxic?! , 2005 .

[5]  V. Rivarola,et al.  Porphyrin-fullerene C60 Dyads with High Ability to Form Photoinduced Charge-separated State as Novel Sensitizers for Photodynamic Therapy¶ , 2005, Photochemistry and photobiology.

[6]  A. Buchachenko,et al.  Spin biochemistry: intramitochondrial nucleotide phosphorylation is a magnesium nuclear spin controlled process. , 2005, Mitochondrion.

[7]  M Sugisaka,et al.  Nanotechnology on duty in medical applications. , 2005, Current pharmaceutical biotechnology.

[8]  P. Hoet,et al.  Nanoparticles – known and unknown health risks , 2004, Journal of nanobiotechnology.

[9]  K. Kano.  Molecular Complexes of Water-Soluble Porphyrins , 2004 .

[10]  Todd Emrick,et al.  Control of protein structure and function through surface recognition by tailored nanoparticle scaffolds. , 2004, Journal of the American Chemical Society.

[11]  N. Martín,et al.  Synthesis and study of novel fulleropyrrolidines bearing biologically active 1,4-dihydropyridines , 2003 .

[12]  H. Penefsky,et al.  Immediate effects of anticancer drugs on mitochondrial oxygen consumption. , 2003, Biochemical pharmacology.

[13]  K. Wallace,et al.  Doxorubicin-induced cardiac mitochondrionopathy. , 2003, Pharmacology & toxicology.

[14]  Q. Pankhurst,et al.  TOPICAL REVIEW: Applications of magnetic nanoparticles in biomedicine , 2003 .

[15]  C. Bárcena,et al.  APPLICATIONS OF MAGNETIC NANOPARTICLES IN BIOMEDICINE , 2003 .

[16]  S. Gad.  Drug Safety Evaluation , 2002 .

[17]  Y. L. Lin,et al.  Light-independent inactivation of dengue-2 virus by carboxyfullerene C3 isomer. , 2000, Virology.

[18]  H. Gaub,et al.  A metal-chelating microscopy tip as a new toolbox for single-molecule experiments by atomic force microscopy. , 2000, Biophysical journal.

[19]  Ravi Kumar M.N.V..  Nano and microparticles as controlled drug delivery devices. , 2000 .

[20]  T. Nagano,et al.  Inhibition of E. coli growth by fullerene derivatives and inhibition mechanism. , 1999, Bioorganic & medicinal chemistry letters.

[21]  Donald J. Birkett,et al.  Pharmacokinetics Made Easy , 1999 .

[22]  Y. Ikada,et al.  Biological functions of fullerene , 1999 .

[23]  A. Seidel,et al.  In Vitro Effects of Fullerene C60 and Fullerene Black on Immuno-Functions of Macrophages , 1996 .

[24]  David F Wilson,et al.  Calibration of oxygen-dependent quenching of the phosphorescence of Pd-meso-tetra (4-carboxyphenyl) porphine: a phosphor with general application for measuring oxygen concentration in biological systems. , 1996, Analytical biochemistry.

[25]  A. V. Govorkov,et al.  Fast estimation of ATP/ADP ratio as a special step in pharmacological and toxicological studies using the cell-free translation systems. , 1986, Journal of biochemical and biophysical methods.

[26]  L. Benet,et al.  Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.

[27]  A. Buchachenko,et al.  Spin biochemistry , 2007, Cell Biochemistry and Biophysics.

[28]  M. Prato,et al.  Synthesis and Biological Properties of Fullerene-Containing Amino Acids and Peptides , 2012 .

[29]  Daniel J Müller,et al.  Imaging and manipulation of biological structures with the AFM. , 2002, Micron.

[30]  A. Starkov,et al.  Mitochondrial targets of drug toxicity. , 2000, Annual review of pharmacology and toxicology.

[31]  S. Vinogradov,et al.  Metallotetrabenzoporphyrins. New phosphorescent probes for oxygen measurements , 1995 .

[32]  J. Willerson.  Molecular and Cellular Cardiology , 1994 .

[33]  D. Morgan,et al.  Clinical Significance of Pharmacokinetic Models of Hepatic Elimination , 1990, Clinical pharmacokinetics.

[34]  D. Tyler,et al.  [11] The preparation of heart mitochondria from laboratory animals , 1967 .